WSGR logoWSGR logo
Erin Boyle Anderson
Patent Agent
Patents and Innovations
San Diego

D858-350-2314

Download vCard
Open PDF

Erin Boyle Anderson is a patent agent in the San Diego office of Wilson Sonsini Goodrich & Rosati, where she is a member of the patents and innovations practice. Erin applies her experience to patent prosecution, freedom-to-operate, and due diligence matters for clients in the biotechnology, diagnostics, and therapeutics industries.

Erin has drafted over 100 U.S. and Patent Cooperation Treaty applications, covering inventions relating to gene therapy, CRISPR, oligonucleotides, peptides and peptide conjugates, personalized medicine, and diagnostics. She has also prosecuted hundreds of U.S. and foreign patent applications, and has performed dozens of freedom-to-operate, diligence, and patent landscape analyses.

Prior to her career in patent law, Erin earned a Ph.D in development, regeneration, and stem cell biology from the University of Chicago. Her graduate work focused on understanding the genetic and developmental factors regulating the migration of fin precursors in zebrafish embryos. This work involved using tools from cell biology, molecular biology, genetics, genomics, and the creation of CRISPR mutants. Prior to graduate school, Erin also worked in Drosophila genetics and plant genetics.

Experience

Erin Boyle Anderson is a patent agent in the San Diego office of Wilson Sonsini Goodrich & Rosati, where she is a member of the patents and innovations practice. Erin applies her experience to patent prosecution, freedom-to-operate, and due diligence matters for clients in the biotechnology, diagnostics, and therapeutics industries.

Erin has drafted over 100 U.S. and Patent Cooperation Treaty applications, covering inventions relating to gene therapy, CRISPR, oligonucleotides, peptides and peptide conjugates, personalized medicine, and diagnostics. She has also prosecuted hundreds of U.S. and foreign patent applications, and has performed dozens of freedom-to-operate, diligence, and patent landscape analyses.

Prior to her career in patent law, Erin earned a Ph.D in development, regeneration, and stem cell biology from the University of Chicago. Her graduate work focused on understanding the genetic and developmental factors regulating the migration of fin precursors in zebrafish embryos. This work involved using tools from cell biology, molecular biology, genetics, genomics, and the creation of CRISPR mutants. Prior to graduate school, Erin also worked in Drosophila genetics and plant genetics.

Focus Areas
Recent Insights
Client Highlights
Wilson Sonsini Advises Janux Therapeutics on Patent Matters Related to License Agreement with Bristol Myers Squibb
On January 22, 2026, Janux Therapeutics (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technologies to its Tumor Activated T Cell Engager (TRACTr), and Tumor Activated Immunomodulator (TRACIr) platforms, announced a collaboration and exclusive worldwide license agreement with Bristol Myers Squibb. Under the terms of the agreement, the companies will develop a tumor-activated therapeutic targeting a validated solid tumor antigen expressed across several human cancer types. Wilson Sonsini Goodrich & Rosati advised Janux on patent matters related to the transaction.
Learn More
Client Highlights
Wilson Sonsini Advises Vida Ventures on IP Matters Related to Third Arc Bio's $165 Million Series A Round
On July 23, 2024, Third Arc Bio Inc., a biotech company developing multifunctional antibodies optimized for T cell engagement across solid tumors and inflammatory & immunology (I&I) disease, announced a $165 million oversubscribed Series A financing that will advance the company through clinical studies to address significant unmet needs in oncology and autoimmunity. The company was launched in 2022 with seed financing from Omega Funds and has since advanced multiple programs that will enter the clinic starting in early 2025. The Series A investor syndicate was led by Vida Ventures and co-led by Cormorant Asset Management and Hillhouse Investment. Omega Funds continued their strong support of the company in the Series A and additional investors include Goldman Sachs Alternatives, BVF Partners LP, funds and accounts advised by T. Rowe Price Associates, Inc., Janus Henderson Investors, funds managed by abrdn Inc., Marshall Wace, Foresite Capital, Logos Capital, Freepoint Capital Group, and AbbVie Ventures.
Learn More
View All
WSGR logo
Copyright © 2026 Wilson Sonsini Goodrich & Rosati. All Rights Reserved.